A study by Aronne et al. investigated the effects of the dual GLP1/GIP receptor agonist (RA) tirzepatide in obese patients when it is administered over a longer period of therapy and the effects of discontinuation. Interesting new findings were also published on the GLP-1 RA semaglutide. McGowan et al. looked at the effects in obese patients with prediabetes, while Deanfield et al. investigated possible cardioprotective effects in obesity and comorbid atherosclerotic cardiovascular disease.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Current status and future prospects
Cell and gene therapies in modern cardiology
- Patient-oriented recommendations for action
Effect of heat on diabetes technology
- Cardiovascular risk and obesity
Pathomechanisms, secondary prevention and treatment options
- Ventricular arrhythmias
Indication for ICD or WCD?
- Early breast cancer
Overweight and obesity worsen the prognosis
- Psoriasis treatment with biologics
What are the latest trends?
- Flu vaccination for older people
Benefit of the high-dose influenza vaccine
- Findings from the ALS Symposium 2024 in Montreal